Results 11 to 20 of about 2,243,298 (271)

Diagnostic Microdosing Approach to Study Gemcitabine Resistance [PDF]

Chemical Research in Toxicology, 2016
Gemcitabine metabolites cause the termination of DNA replication and induction of apoptosis. We determined whether subtherapeutic "microdoses" of gemcitabine are incorporated into DNA at levels that correlate to drug cytotoxicity. A pair of nearly isogenic bladder cancer cell lines differing in resistance to several chemotherapy drugs were treated with
Scharadin, Tiffany M, Zhang, Hongyong, Zimmermann, Maike, Wang, Sisi, Malfatti, Michael A, Cimino, George D, Turteltaub, Kenneth, de Vere White, Ralph, Pan, Chong-xian, Henderson, Paul T   +9 more
openaire   +6 more sources

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Cancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao   +19 more
doaj   +2 more sources

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. [PDF]

PLoS ONE, 2012
BACKGROUND: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent.
Myrna Candelaria, Erick de la Cruz-Hernandez, Lucia Taja-Chayeb, Enrique Perez-Cardenas, Catalina Trejo-Becerril, Aurora Gonzalez-Fierro, Alma Chavez-Blanco, Ernesto Soto-Reyes, Guadalupe Dominguez, Jaenai E Trujillo, Jose Diaz-Chavez, Alfonso Duenas-Gonzalez   +11 more
doaj   +2 more sources

Targeting ketone body metabolism in mitigating gemcitabine resistance. [PDF]

JCI Insight
Chemotherapy is often combined with surgery for muscle invasive and nonmuscle invasive bladder cancer (BCa). However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark in cancer chemoresistance.
Rohena-Rivera K, You S, Kim M, Billet S, Ten Hoeve J, Gonzales G, Huang C, Heard A, Chan KS, Bhowmick NA.   +9 more
europepmc   +3 more sources

CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.

PLoS ONE
Gemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit.
Kun-Lin Hsieh, Kuan-Hua Huang, Ching-Ping Chang, Hung-Wen Tsai, Yu-Hao Chang, Yi-Ru Zheng, Huei-Sheng Huang   +6 more
doaj   +2 more sources

The Role of Dicer Phosphorylation in Gemcitabine Resistance of Pancreatic Cancer. [PDF]

Int J Mol Sci
Dicer, a cytoplasmic type III RNase, is essential for the maturation of microRNAs (miRNAs) and is implicated in cancer progression and chemoresistance. Our previous research demonstrated that phosphorylation of Dicer at S1016 alters miRNA maturation and glutamine metabolism, contributing to gemcitabine (GEM) resistance in pancreatic ductal ...
Chiu CF, Lin HR, Su YH, Chen HA, Hung SW, Huang SY.   +5 more
europepmc   +3 more sources

Ferroptosis Suppression by the M⁶A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. [PDF]

Adv Sci (Weinh)
IGF2BP1 promotes gemcitabine resistance in pancreatic cancer by stabilizing m6A‐modified FTH1 transcripts and protecting them in stress granules, thereby suppressing ferroptosis. Pharmacological inhibition of IGF2BP1 disrupts this protective pathway, restores ferroptotic sensitivity, and enhances gemcitabine efficacy in resistant tumors.
Zhu YQ, Huang Y, Ye JY, Lu SY, Liu ZD, Ma MJ, Fang DL, Zhao ZY, Xie JZ, Chen J, Yin XY.   +10 more
europepmc   +2 more sources

Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]

Research in Oncology, 2021
Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei, Eman Dessouky, Thanaa I. Shalaby, Sarah K. Amer, Rasha Nassra   +4 more
doaj   +1 more source

Review of molecular mechanisms underlying gemcitabine resistance in pancreatic cancer [PDF]

The Journal of Qazvin University of Medical Sciences, 2017
Pancreatic cancer is one the most malignant cancers in human. A great percentage of patients die annually due to lack of early detection as well as efficient treatment strategies. Only five-year survival rate is still only seen in 5% of patients.
A. Rajabpour, L. Teimoori Toolabi, F. Rajaei   +2 more
doaj   +1 more source

Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma. [PDF]

Cancers (Basel)
Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings.
Yamashita T, Nagamoto S, Arai M, Kitayama S, Yano A, Higashi M.   +5 more
europepmc   +2 more sources